Full Press Release Details
Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product and Place with Executive and Consultant Guides and Impact of Artificial Intelligence" report has been added to ResearchAndMarkets.com's offering.
The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.The report includes five year market forecasts.
Cancer Molecular Diagnostics is back on the growth path. And growth is accelerating in every segment. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. Over 140 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.
Exciting technical developments especially in companion diagnostics, hold the promise of a dynamic, growing and evolving world market where single laboratories serve a global patient base.
Molecular Diagnostics for Cancer provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.
Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.
Personalized medicine
Minimal residual disease testing
Emergence of new economies with large markets
Physician diagnostics being displaced by new intelligent diagnostic tests
1.1 Cancer MDx - Strategic Situation Analysis
1.2 Guide for Executives, Marketing, and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors
1.4 Impact of Artificial Intelligence on Cancer MDx
2 Introduction and Market Definition
2.1 What are Molecular Diagnostics?
2.2 The Diagnostics Revolution
2.3 Market Definition
2.3.1 Revenue Market Size
2.5 Perspective: Healthcare Spending
2.5.1 Global Healthcare Spending
2.5.2 Spending on Healthcare and Pharmaceuticals
2.5.3 Spending on Diagnostics
2.5.4 Important Role of Insurance for Medical Services
3.1.1 Traditional Market Segmentation
3.1.2 Laboratory Focus and Segmentation
3.2 Industry Structure
3.2.1 Hospital Testing Share
3.2.2 Economies of Scale
3.2.3 Physician Office Labs
3.2.4 Physician's and POCT
4.1 Factors Driving Growth
4.1.1 New Diagnostics Create New Markets
4.1.2 New Roles for Diagnostics
4.1.4 Expanding the Pharmaceutical Toolbox
4.1.5 Regulatory Retreat
4.2 Factors Limiting Growth
4.2.1 Falling Prices
4.2.3 Wellness has a Downside
4.3 Instrumentation, Automation and Diagnostic Trends
4.3.1 Traditional Automation and Centralization
4.3.2 The New Automation, Decentralization and Point Of Care
4.3.3 Instruments Key to Market Share
4.3.4 Bioinformatics Plays a Role
4.3.5 PCR Takes Command
4.3.6 Next Generation Sequencing Fuels a Revolution
4.3.7 NGS Impact on Pricing
4.3.8 Whole Genome Sequencing, A Brave New World
4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment
4.3.10 Shifting Role of Diagnostics
4.3.11 Multiplexing and Foundation One
4.3.12 Pharmacogenomics Technology
4.3.13 Gene Editing and Gene Therapy
5 Molecular Diagnostics Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.2 Biodesix Revenues up
5.3 Waters to buy Becton unit
5.4 QuidelOrtho refocuses with LEX acquisition
5.5 Guardant Health Guardant360 Tissue
5.6 AccuStem Sciences & EmeritusDx partner for Lung Cancer Screening
5.7 LetsGetChecked LaunchesHereditary Cancer Test
5.8 Guardant Health's Colorectal Test New Status
5.10 OneCell Diagnostics Raises $16M
5.11 A. Menarini to use Nucleix Bladder Cancer Test
5.12 Foundation Medicine, Repare Therapeutics to Develop CDx
5.13 NHS Declines to Accelerate Grail Galleri Implementation
5.14 GeneDx Sees Growing Demand for Testing
5.15 Thermo Fisher and Bayer to Develop CDx for Cancer Therapies
5.16 ClearNote Health Expands Into Immunotherapy Monitoring
5.17 Foundation Medicine to Collaborate on CDx for Lung Cancer
5.18 Qiagen and Myriad Genetics Partner to Develop Cancer CDx
5.19 Lung Cancer Data Heralds Shift for Hummingbird Dx
5.20 PamGene Awarded €7.5M for Immunotherapy Test
5.21 Grail Cancer Test Faces New Clinical Questions
5.22 Freenome Acquires Cancer Dx Firm Oncimmune
5.23 Quest Diagnostics to Acquire Liquid Biopsy Firm Haystack Oncology
5.24 Ultima Genomics, Genome Insight Partner on WGS for Cancer Patients
5.25 Digital Pathology Meets Cancer Sequencing
5.26 Exact Sciences Preps Expanded Oncology Portfolio
5.27 Qiagen Details Oncology Plans for Digital PCR Platform
5.28 Sema4 Exiting Reproductive Health Screening
5.29 Thermo Fisher Introduces Cancer Profiling Assay
5.30 Genomic Test IDs Cysts Likely to Progress to Cancer
5.31 Naveris to Commercialize Virus-Related Cancer Tests
5.32 Larger Liquid Biopsy Panels Loom
5.33 Halo Diagnostics to Offer Genomic Profiling Tests
5.34 BillionToOne Raises $125M
5.35 Local Cancer Genomic Profiling Options Grow
5.36 German MDx Firm Mainz Biomed Raises $10M in IPO
5.37 Guardant Health Q3 Revenues Up 27 Percent
5.38 BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection
5.39 Nucleix to Invest in Early-Stage Lung Cancer Dx
5.40 Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics
5.41 Grail Gets Approval for Galleri Multicancer Test
5.42 Finnish Firms to Form Point-of-Care Testing Firm
5.43 Datar Cancer Genetics Expands to Dx and Screening
5.44 HTG Molecular Diagnostics: HTG Transcriptome Panel
5.45 PacBio's Omniome Acquisition Shortens Path to Clinical